PROTAC Technology: A New Paradigm for Targeted Protein Degradation

What Is a PROTAC?

PROTACs (PROteolysis TArgeting Chimeras) are bifunctional small molecules designed to degrade target proteins via the ubiquitin-proteasome system. Unlike classical inhibitors, they eliminate — rather than simply block — their targets.

Pharmacological Advantages

The defining feature of PROTACs is their catalytic mode of action: a single PROTAC molecule can drive the degradation of multiple copies of the target protein before being released to engage another E3 ligase. This sub-stoichiometric activity translates to efficacy at lower drug concentrations compared to occupancy-driven inhibitors.

Perhaps more importantly, PROTACs can engage "undruggable" targets — transcription factors and scaffolding proteins that lack a catalytic pocket — opening new therapeutic avenues in oncology.

Clinical Progress

As of 2024, several PROTAC candidates have entered Phase I/II trials. ARV-110 (bavdegalutamide) and ARV-471 (vepdegestrant), targeting the androgen and estrogen receptors respectively, are among the most advanced.

Outlook

The field faces real challenges — oral bioavailability, cell permeability, and the hook effect at high concentrations — but the pace of development is rapid. PROTACs represent a genuine shift in how we think about small-molecule therapeutics.